Drug intelligence / Profile preview

APB-R5

Development stage: Preclinical
Lead developer: Aprilbio
Modality: Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
Administration: Subcutaneous

Overview

APB-R5 is a novel drug candidate being co-developed by AprilBio Co. Ltd. and Yuhan Corp. for the treatment of intractable solid cancers. It is being developed using AprilBio's proprietary SAFA (Sustained Antibody Fc-fusion Approach) platform technology, which is designed to create dual- and long-acting fusion proteins. The collaboration aims to leverage AprilBio's SAFA platform and dual-action anticancer drug development technology with Yuhan's immunotherapy development expertise to create a substance that can safely and effectively remove cancer cells.

Beyond the preview

Go deeper on APB-R5.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on APB-R5.

Explore the full profile